RVMDNasdaq,Nasdaq SEC EDGAR

Revolution Medicines, Inc.

Biological Products, (No Diagnostic Substances)·REDWOOD CITY, CA·FY end 12/31·CIK 1628171

CEO Pay Ratio

—

CEO Total Comp

—

Median Employee

$433,964

Revenue

FY 2025

Net Income

-$1.1B

FY 2025

Free Cash Flow

-$913.7M

FY 2025

Net Margin

—

Insider Net (180d)

-$38.2M

0 buys / 38 sales

CEO Pay Accountability

CEO comp as % of net income

—

Not enough data to compute.

CEO comp as % of buybacks

—

No buyback data for the most recent fiscal year.

5-year history · USD

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	Trend
Revenue	$0	$0	$11.6M	$35.4M	$29.4M
Gross Profit	—	—	—	—	—	—
Operating Income	-$1.2B	-$689.5M	-$487.2M	-$258.3M	-$188.0M
Net Income	-$1.1B	-$600.1M	-$436.4M	-$248.7M	-$187.1M
Operating CF	-$897.7M	-$557.4M	-$350.6M	-$224.4M	-$147.2M
Capex	$16.0M	$10.3M	$7.7M	$10.8M	$6.5M
Free Cash Flow	-$913.7M	-$567.7M	-$358.3M	-$235.2M	-$153.7M
Buybacks	—	—	—	—	—	—
Dividends	—	—	—	—	—	—

Gross Margin	—	—	—	—	—	—
Operating Margin	—	—	-4207.1%	-730.0%	-639.7%
Net Margin	—	—	-3768.3%	-703.0%	-636.6%
FCF Margin	—	—	-3094.1%	-664.8%	-523.0%
R&D / Revenue	—	—	3654.1%	715.3%	636.1%
Effective Tax	0.0%	0.1%	0.8%	0.2%	0.0%
Debt / Equity	—	—	—	—	—	—
Buybacks / FCF	—	—	—	—	—	—

FY 2025

Executive	Salary	Stock	Options	Bonus / Inc.	Other	Total
Mark A. GoldsmithM.D., Ph.D.	$812.5K	$4.0M	$9.0M	$889.7K	$7.0K	$14.7M
Stephen M. KelseyM.D., FRCP, FRCPath	$625.8K	$1.5M	$3.4M	$461.2K	$7.0K	$6.0M
Margaret HornJ.D.	$582.7K	$1.2M	$2.6M	$426.5K	$7.0K	$4.8M
Jeffrey Cislini	$523.8K	$896.3K	$2.0M	$261.0K	$7.0K	$3.7M
Jack AndersChief Financial Officer	$523.3K	$831.1K	$1.9M	$343.8K	$7.0K	$3.6M
General Counsel andSecretary	$477.2K	$625.8K	$1.4M	$217.2K	$7.0K	$2.7M